Dihydromyricetin improves colonic mucosal barrier function in mice with metabolism-associated fatty liver disease

Ling JIANG; Pengfei LI; Pengfei HOU; Jie ZHOU; Niu DONG; Qianyong ZHANG; Long YI; Mantian MI

doi:10.16016/j.2097-0927.202206187

您当前的位置：

首页 >

文章列表页 >

Dihydromyricetin improves colonic mucosal barrier function in mice with metabolism-associated fatty liver disease

Basic Medicine | 更新时间：2026-01-09

- Dihydromyricetin improves colonic mucosal barrier function in mice with metabolism-associated fatty liver disease
- Journal of Army Medical University Vol. 45, Issue 2, Pages: 146-154(2023)
- 作者机构：
  
  400038 重庆，陆军军医大学(第三军医大学)军事预防医学系军队营养与食品安全研究中心，重庆市医学营养研究中心，重庆市营养与食品安全重点实验室
- 作者简介：
- 基金信息：
  
  the General Program of National Natural Science Foundation of China(81872625);the General Program of National Natural Science Foundation of China(82173505)
- DOI：10.16016/j.2097-0927.202206187
  CLC： R285.5;R333.3;R575.5
- Received：29 June 2022，
  
  Revised：2022-08-18，
  
  Published：30 January 2023
- 稿件说明：
移动端阅览
Ling JIANG, Pengfei LI, Pengfei HOU, et al. Dihydromyricetin improves colonic mucosal barrier function in mice with metabolism-associated fatty liver disease[J]. Journal of Army Medical University, 2023, 45(2): 146-154.
DOI：

Ling JIANG, Pengfei LI, Pengfei HOU, et al. Dihydromyricetin improves colonic mucosal barrier function in mice with metabolism-associated fatty liver disease[J]. Journal of Army Medical University, 2023, 45(2): 146-154. DOI： 10.16016/j.2097-0927.202206187.

摘要

目的

研究二氢杨梅素(dihydromyricetin

DHM)对代谢相关脂肪性肝病(metabolic-associated fatty liver disease

MAFLD)的改善作用

并揭示其调节肠黏膜屏障功能的作用机制。

方法

32只雄性C57BL/6J小鼠随机分为4组(

=8): CON (对照

脂肪供能比为10%饮食)组、高脂饮食(HFD

脂肪供能比为45%)组、HFD+DHM组(添加质量比0.6% DHM的高脂饲料)和DHM组(添加质量比0.6% DHM的对照饲料)

干预12周。每周测量小鼠体质量、摄食量; 处死前进行空腹血糖、葡萄糖耐量和肠道通透性检测; 试剂盒检测血清生化指标、脂多糖(LPS); 肝组织进行油红O染色和HE染色

观察组织病理学变化; RT-qPCR和Western blot法检测肠上皮紧密连接蛋白、抗菌肽及肝脏炎症因子表达水平; 流式细胞术检测结肠3型固有淋巴样细胞(group 3 innate lymphoid cells

ILC3)比例以及IL-22表达水平。

结果

与CON组比较

HFD组小鼠体质量增加

糖耐量受损

血清总胆固醇、甘油三酯、谷丙转氨酶、谷草转氨酶升高

肝脏脂质沉积和炎性因子

-1

、

-6、

TNF

mRNA表达水平升高

肠道通透性和血清LPS增加

肠黏膜紧密连接蛋白

-1、

Occludin

及抗菌肽

Reg

Ⅲ

、

Reg

Ⅲ

表达水平降低

结肠ILC3及IL-22

ILC3比例降低(

0.05)。与HFD组比较

HFD+DHM组糖耐量受损明显改善

肝脏脂质沉积和炎性因子表达减少

血清LPS水平降低

肠紧密连接蛋白和抗菌肽表达水平增加

肠道通透性减少

结肠ILC3和IL-22

ILC3比例增加(

0.05)。

结论

DHM可能通过改善肠黏膜屏障功能减少肝脏脂质堆积和炎症反应

改善MAFLD疾病进程。

Abstract

Objective

To investigate the ameliorative effects of dihydromyricetin (DHM) on metabolism-associated fatty liver disease (MAFLD)

and to reveal the mechanism of its regulation of intestinal mucosal barrier function.

Methods

Thirty-two male C57BL/6J mice were randomly divided into 4 groups (

=8): CON (control diet

with 10% fat) group

HFD (high-fat diet

with 45% fat) group

HFD+DHM (high-fat diet+0.6% DHM) group

and DHM (control diet+0.6% DHM) gro

up.All the subjects were intervened for 12 weeks

the body weight and food consumption of mice were measured weekly.Fasting blood glucose

glucose tolerance and intestinal permeability were tested before sacrifice.Serum levels of biochemical indexes and lipopolysaccharide (LPS) were detected with corresponding kits.The liver tissues were stained with HE and oil red O staining

respectively

and the histopathological changes were observed.Moreover

RT-qPCR and Western blotting were used to measure the expression levels of intestinal epithelial tight junction proteins

antimicrobial peptides and liver inflammatory factors.Flow cytometry was adopted to determine the proportion of group 3 innate lymphoid cells (ILC3) and the level of IL-22 in the colon.

Results

As compared with the CON group

the HFD group presented increased body weight

impaired glucose tolerance

as well as elevated serum total cholesterol

triglyceride

alanine transaminase and aspartate transaminase.HFD also led to liver lipid deposition and higher mRNA levels of

-1

-6 and

TNF

in the liver.The intestinal permeability and serum LPS were increased

whereas the expression levels of tight junction proteins

-1 and

Occludin

and antimicrobial peptides

Reg

Ⅲ

and

Reg

Ⅲ

in the intestinal mucosa were decreased

and the proportions of ILC3 and IL-22

ILC3 in the colon were declined (

0.05).In the HFD+DHM group

the impaired glucose tolerance was significantly improved

the hepatic lipid deposition and the expression of inflammatory factors were reduced

so was the serum LPS level.DHM also upregulated the levels of intestinal tight junction proteins and antimicrobial peptides

and ameliorated the intestinal permeability.Furthermore

the colonic ILC3 and IL-22

ILC3 ratios were increased b

y DHM treatment as well (

0.05).

Conclusion

DHM may ameliorate the progression of MAFLD by improving intestinal barrier function to reduce lipid accumulation and inflammatory responses in the liver.

关键词

Keywords

references

ESLAM M, SANYAL A J, GEORGE J, et al . MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J ] . Gastroenterology, 2020, 158(7): 1999-2014. e1. DOI: 10.1053/j.gastro.2019.11.312.

YOUNOSSI Z, ANSTEE Q M, MARIETTI M, et al . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J ] . Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109.

MOORE M P, CUNNINGHAM R P, DASHEK R J, et al . A fad too far? Dietary strategies for the prevention and treatment of NAFLD[J ] . Obesity (Silver Spring), 2020, 28(10): 1843-1852. DOI: 10.1002/oby.22964.

TONG H H, ZHANG X J, TAN L F, et al . Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases[J ] . Eur J Pharmacol, 2020, 870: 172888. DOI: 10.1016/j.ejphar.2019.172888.

CHEN S H, ZHAO X L, WAN J, et al . Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: a randomized controlled trial[J ] . Pharmacol Res, 2015, 99: 74-81. DOI: 10.1016/j.phrs.2015.05.009.

ZENG X L, YANG J N, HU O, et al . Dihydromyricetin ameliorates nonalcoholic fatty liver disease by improving mitochondrial respiratory capacity and redox homeostasis through modulation of SIRT3 signaling[J ] . Antioxid Redox Signal, 2019, 30(2): 163-183. DOI: 10.1089/ars.2017.7172.

ZHOU X, YU L, ZHOU M, et al . Dihydromyricetin ameliorates liver fibrosis via inhibition of hepatic stellate cells by inducing autophagy and natural killer cell-mediated killing effect[J ] . Nutr Metab (Lond), 2021, 18(1): 64. DOI: 10.1186/s12986-021-00589-6.

HUANG L, ZENG X L, LI B, et al . Dihydromyricetin attenuates palmitic acid-induced oxidative stress by promoting autophagy via SIRT3-ATG4B signaling in hepato cytes[J ] . Nutr Metab (Lond), 2021, 18(1): 83. DOI: 10.1186/s12986-021-00612-w.

余利, 蒋玲, 周杰, 等. 小鼠肠道3型固有淋巴样细胞检测与分析方法研究[J]. 局解手术学杂志, 2022, 31(2): 113-118.

YU L, JIANG L, ZHOU J, et al . Detection and analysis method of group 3 innate lymphoid cells in miceintestine[J ] . J Reg Anat Oper Surg, 2022, 31(2): 113-118.

ZHOU J H, ZHOU F, WANG W X, et al . Epidemiological features of NAFLD from 1999 to 2018 in China[J ] . Hepatology, 2020, 71(5): 1851-1864. DOI: 10.1002/hep.31150.

ESTES C, ANSTEE Q M, ARIAS-LOSTE M T, et al . Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J ] . J Hepatol, 2018, 69(4): 896-904. DOI: 10.1016/j.jhep.2018.05.036.

BUZZETTI E, PINZANI M, TSOCHATZIS E A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048. DOI: 10.1016/j.metabol.2015.12.012.

LI X Y, WANG H. Multiple organs involved in the pathogenesis of non-alcoholic fatty liver disease[J]. Cell Biosci, 2020, 10(1): 140. DOI: 10.1186/s13578-020-00507-y.

ZHANG X, JI X T, WANG Q, et al . New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J ] . Protein Cell, 2018, 9(2): 164-177. DOI: 10.1007/s13238-017-0436-0.

GHOSH S S, HE H L, WANG J, et al . Curcumin-mediated regulation of intestinal barrier function: the mechanism underlying its beneficial effects[J ] . Tissue Barriers, 2018, 6(1): e1425085. DOI: 10.1080/21688370.2018.1425085.

ZHANG X Y, CHEN J, YI K, et al . Phlorizin ameliorates obesity-associated endotoxemia and insulin resistance in high-fat diet-fed mice by targeting the gut microbiota and intestinal barrier integrity[J ] . Gut Microbes, 2020, 12(1): 1-18. DOI: 10.1080/19490976.2020.1842990.

DONG S J, ZHU M, WANG K, et al . Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism[J ] . Pharmacol Res, 2021, 171: 105767. DOI: 10.1016/j.phrs.2021.105767.

GOTO Y, OBATA T, KUNISAWA J, et al . Innate lymphoid cells regulate intestinal epithelial cell glycosylation[J ] . Science, 2014, 345(6202): 1254009. DOI: 10.1126/science.1254009.

ZELANTE T, IANNITTI R G, CUNHA C, et al . Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22[J ] . Immunity, 2013, 39(2): 372-385. DOI: 10.1016/j.immuni.2013.08.003.

PATNAUDE L, MAYO M, MARIO R, et al . Mechanisms and regulation of IL-22-mediated intestinal epithelial homeostasis and repair[J ] . Life Sci, 2021, 271: 119195. DOI: 10.1016/j.lfs.2021.119195.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Screening and validation of key molecular targets for dihydromyricetin in ameliorating diabetic nephropathy

Dihydromyricetin induces mitophagy by regulating Prohibitin 2 pathway in vascular endothelial cells

Dihydromyricetin improves rhythm disorder in expression of liver circadian clock genes in non-alcoholic fatty liver mice

Dihydromyricetin inhibits migration and invasion of human breast cancer cells by suppressing mTOR signaling pathway

Dihydromyricetin attenuates activation of hepatic stellate cells through TGF-β1/Smad signaling pathway

Related Author

LIU Xingran

NIU Mengzhu

GAO Yuan

CHEN Dandan

ZHANG Baowen

LIU Dekun

LIU Xiaoqian

KOU Xianjuan

Related Institution

College of Sports Medicine， Wuhan Sports University

College of Physical Education and Health， Guangxi Medical University

School of Sports Science and Health， Harbin Sport University

School of Physical Education， Guangxi University of Science and Technology

Hubei Key Laboratory of Sport Training and Monitoring

⁰